ORCID Profile
0000-0003-1215-9791
Current Organisation
Universitat Politècnica de Catalunya
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Research Topics
In Research Link Australia (RLA), "Research Topics" refer to ANZSRC FOR and SEO codes. These topics are either sourced from ANZSRC FOR and SEO codes listed in researchers' related grants or generated by a large language model (LLM) based on their publications.
Top 5 Research Topics
ANZSRC Field of Research (FoR)
Proteomics and Intermolecular Interactions (excl. Medical Proteomics) | Industrial Biotechnology not elsewhere classified | Industrial Biotechnology | Functional Materials | Biochemistry and Cell Biology
ANZSRC Socio-Economic Objective (SEO)
Human Pharmaceutical Products not elsewhere classified | Veterinary Pharmaceutical Products not elsewhere classified | Expanding Knowledge in the Biological Sciences |
Related Links
Publications
Magnetic nanodrug delivery in non-Newtonian blood flows
Publisher: Springer Science and Business Media LLC
Date: 04-09-2022
DOI: 10.1007/S10404-022-02576-6
Abstract: With the goal of determining strategies to maximise drug delivery to a specific site in the body, we developed a mathematical model for the transport of drug nanocarriers (nanoparticles) in the bloodstream under the influence of an external magnetic field. Under the assumption of long (compared to the radius) blood vessels the Navier-Stokes equations are reduced, to a simpler model consistently with lubrication theory. Under these assumptions, analytical results are compared for Newtonian, power-law, Carreau and Ellis fluids, and these clearly demonstrate the importance of shear thinning effects when modelling blood flow. Incorporating nanoparticles and a magnetic field to the model we develop a numerical scheme and study the particle motion for different field strengths. We demonstrate the importance of the non-Newtonian behaviour: for the flow regimes investigated in this work, consistent with those in blood micro vessels, we find that the field strength needed to absorb a certain amount of particles in a non-Newtonian fluid has to be larger than the one needed in a Newtonian fluid. Specifically, for one case examined, a two times larger magnetic force had to be applied in the Ellis fluid than in the Newtonian fluid for the same number of particles to be absorbed through the vessel wall. Consequently, models based on a Newtonian fluid can drastically overestimate the effect of a magnetic field. Finally, we evaluate the particle concentration at the vessel wall and compute the evolution of the particle flux through the wall for different permeability values, as that is important when assessing the efficacy of drug delivery applications. The insights from our work bring us a step closer to successfully transferring magnetic nanoparticle drug delivery to the clinic.
Ambient Temperature Stable, Scalable COVID‐19 Polymer Particle Vaccines Induce Protective Immunity
Publisher: Wiley
Date: 10-11-2021
Abstract: There is an unmet need for safe and effective severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines that are stable and can be cost‐effectively produced at large scale. Here, a biopolymer particle (BP) vaccine technology that can be quickly adapted to new and emerging variants of SARS‐CoV‐2 is used. Coronavirus antigen‐coated BPs are described as vaccines against SARS‐CoV‐2. The spike protein subunit S1 or epitopes from S and M proteins (SM) plus/minus the nucleocapsid protein (N) are selected as antigens to either coat BPs during assembly inside engineered Escherichia coli or BPs are engineered to specifically ligate glycosylated spike protein (S1‐ICC) produced by using baculovirus expression in insect cell culture (ICC). BP vaccines are safe and immunogenic in mice. BP vaccines, SM‐BP‐N and S1‐ICC‐BP induced protective immunity in the hamster SARS‐CoV‐2 infection model as shown by reduction of virus titers up to viral clearance in lungs post infection. The BP platform offers the possibility for rapid design and cost‐effective large‐scale manufacture of ambient temperature stable and globally available vaccines to combat the coronavirus disease 2019 (COVID‐19) pandemic.
Mathematical modelling of carbon capture in a packed column by adsorption
Publisher: Elsevier BV
Date: 11-2020
Advanced liquid biopsy technologies for circulating biomarker detection
Publisher: Royal Society of Chemistry (RSC)
Date: 2019
DOI: 10.1039/C9TB01490J
Abstract: In this review, we have summarised the biogenesis, biological significance, isolation and detection technologies of four widely known circulating biomarkers namely circulating tumour cells, circulating tumor specific DNA, microRNA, and exosomes.
Modelling nanocrystal growth via the precipitation method
Publisher: Elsevier BV
Date: 02-2021
Particulate Mycobacterial Vaccines Induce Protective Immunity against Tuberculosis in Mice
Publisher: MDPI AG
Date: 13-08-2021
DOI: 10.3390/NANO11082060
Abstract: Currently available vaccines fail to provide consistent protection against tuberculosis (TB). New, improved vaccines are urgently needed for controlling the disease. The mycobacterial antigen fusions H4 (Ag85B-TB10.4) and H28 (Ag85B-TB10.4-Rv2660c) have been shown to be very immunogenic and have been considered as potential candidates for TB vaccine development. However, soluble protein vaccines are often poorly immunogenic, but augmented immune responses can be induced when selected antigens are delivered in particulate form. This study investigated whether the mycobacterial antigen fusions H4 and H28 can induce protective immunity when assembled into particulate vaccines (polyester nanoparticle-H4, polyester nanoparticle-H28, H4 nanoparticles and H28 nanoparticles). The particulate mycobacterial vaccines were assembled inside an engineered endotoxin-free production strain of Escherichia coli at high yield. Vaccine nanoparticles were purified and induced long-lasting antigen-specific T cell responses and protective immunity in mice challenged by aerosol with virulent Mycobacterium tuberculosis. A significant reduction of M. tuberculosis CFU, up to 0.7-log10 protection, occurred in the lungs of mice immunized with particulate vaccines in comparison to placebo-vaccinated mice (p 0.0001). Polyester nanoparticles displaying the mycobacterial antigen fusion H4 induced a similar level of protective immunity in the lung when compared to M. bovis bacillus Calmette-Guérin (BCG), the currently approved TB vaccine. The safe and immunogenic polyester nanoparticle-H4 vaccine is a promising subunit vaccine candidate, as it can be cost-effectively manufactured and efficiently induces protection against TB.
Environmental applications of adsorption technology: From the experimental research to the mathematical modeling of the breakthrough curves
Publisher: Grupo Pacífico
Date: 08-05-2023
Modelling carbon capture by adsorption (and why standard models fail)
Publisher: Grupo Pacífico
Date: 04-05-2023
On the one-phase reduction of the Stefan problem with a variable phase change temperature
Publisher: Elsevier BV
Date: 02-2015
A Mathematical Model of Carbon Capture by Adsorption
Publisher: Springer International Publishing
Date: 16-12-2021
A mathematical model for the energy stored in green roofs
Publisher: Elsevier BV
Date: 03-2023
Multidisciplinary Mathematical Modelling
Publisher: Springer International Publishing
Date: 2021
Epitope-coated polymer particles elicit neutralising antibodies against Plasmodium falciparum sporozoites
Publisher: Springer Science and Business Media LLC
Date: 29-11-2021
DOI: 10.1038/S41541-021-00408-2
Abstract: The current Malaria RTS,S vaccine is based on virus-like particles (VLPs) comprising the NANP repetitive epitopes from the cicumsporozoite protein (CSP) of Plasmodium falciparum . This vaccine has limited efficacy, only preventing severe disease in about 30% of vaccinated in iduals. A more efficacious vaccine is urgently needed to combat malaria. Here we developed a particulate malaria vaccine based on the same CSP epitopes but using biopolymer particles (BPs) as an antigen carrier system. Specific B- and T-cell epitope-coated BPs were assembled in vivo inside an engineered endotoxin-free mutant of Escherichia coli . A high-yield production process leading to ~27% BP vaccine weight over biomass was established. The epitope-coated BPs were purified and their composition, i.e., the polymer core and epitope identity, was confirmed. Epitope-coated BPs were used alongside soluble peptide epitopes and empty BPs to vaccinate sheep. Epitope-coated BPs showed enhanced immunogenicity by inducing anti-NANP antibody titre of EC50 150,000 that were at least 20 times higher than induced by the soluble peptides. We concluded that the additional T-cell epitope was not required as it did not enhance immunogenicity when compared with the B-cell epitope-coated BPs. Antibodies specifically bound to the surface of Plasmodium falciparum sporozoites and efficiently inhibited sporozoite motility and traversal of human hepatocytes. This study demonstrated the utility of biologically self-assembled epitope-coated BPs as an epitope carrier for inclusion in next-generation malaria vaccines.
Mass transfer from a fluid flowing through a porous media
Publisher: Elsevier BV
Date: 12-2020
Continuum mathematics at the nanoscale
Publisher: Springer Science and Business Media LLC
Date: 2014
Modelling mass transfer from a packed bed by fluid extraction
Publisher: Elsevier BV
Date: 06-2022
Energy conservation in the one-phase supercooled Stefan problem
Publisher: Elsevier BV
Date: 12-2012
Polyester as Antigen Carrier toward Particulate Vaccines
Publisher: American Chemical Society (ACS)
Date: 24-05-2019
DOI: 10.1021/ACS.BIOMAC.9B00509
Abstract: Spherical polyhydroxyalkanoate (PHA) inclusions are naturally self-assembled inside bacteria. These PHA beads are shell-core structures composed of a hydrophobic PHA core surrounded by proteins, such as PHA synthase (PhaC). PhaC is covalently attached and serves as an anchor protein for foreign protein vaccine candidate antigens. PHA beads displaying single and multiple antigens showed enhanced immunological properties when compared to respective soluble vaccines. This review highlights the unique design space of the PHA bead-based vaccines toward the development of safe and synthetic particulate vaccines. The PHA bead technology will be compared with chemically synthesized polyesters, such as polylactic acids, formulated to deliver vaccine antigens. The performance of PHA bead vaccine candidates to induce specific immune responses and protective immunity against bacterial and viral pathogens in animal trials will be summarized. We propose that the PHA bead technology offers a versatile vaccine platform for design and cost-effective manufacture of synthetic multivalent vaccines.
One-dimensional solidification of supercooled melts
Publisher: Elsevier BV
Date: 07-2013
Bioengineered Polymer Nanobeads for Isolation and Electrochemical Detection of Cancer Biomarkers
Publisher: American Chemical Society (ACS)
Date: 29-06-2021
A mathematical model for nanoparticle melting with density change
Publisher: Springer Science and Business Media LLC
Date: 24-05-2015
Contaminant Removal by Adsorption
Publisher: Springer International Publishing
Date: 2022
In-air particle generation by on-chip electrohydrodynamics
Publisher: Royal Society of Chemistry (RSC)
Date: 2021
DOI: 10.1039/D0LC01247E
Abstract: This work demonstrates the capability of simultaneously generating-and-delivering a stream of micro/nanoparticles range of 0.75–2 μm by electrohydrodynamics, without any restrictions of either the collector or the assistance of external flow.
Spherically symmetric nanoparticle melting with a variable phase change temperature
Publisher: Springer Science and Business Media LLC
Date: 05-11-2013
Related Organisations
Universitat De Vic - Universitat Central De Catalunya
Location: Spain
Related Funding Activities
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE200100140
Start Date: 03-2020
End Date: 06-2021
Amount: $945,000.00
Funder: Australian Research Council
View Funded ActivityDiscovery Projects - Grant ID: DP200100874
Start Date: 03-2020
End Date: 03-2024
Amount: $510,000.00
Funder: Australian Research Council
View Funded Activity